The effect of the suspension of the license for aprotinin on the care of patients undergoing cardiac surgery: a survey of cardiac anesthesiologists' and surgeons' opinions in the United Kingdom.
OBJECTIVE
The primary aim was to poll the opinions of cardiac anesthesiologists and surgeons as to the effect of the suspension of the license for aprotinin on patients undergoing cardiac surgery.


METHODS
A mailed questionnaire.


METHODS
United Kingdom.


METHODS
Members of the Association of Cardiothoracic Anaesthetists and the Society for Cardiothoracic Surgery in Great Britain and Ireland with a UK address.


METHODS
A structured questionnaire.


RESULTS
Of the 546 dispatched surveys, 285 (52%) were returned. While the majority of respondents (61%) felt it had not had any effect, 29% of respondents felt the suspension of the license for aprotinin had had a detrimental effect on patient care and 2% an extremely detrimental effect. Eight percent of respondents reported a beneficial effect. Since license suspension, the reported use of aprotinin had declined and tranexamic acid use had risen. The majority of respondents reported no change in the use of packed red cells (66%), blood products (53%), mechanical cell salvage (84%), factor VIIa (79%), or frequency of reopening for bleeding (65%). Respectively, 32%, 45%, 24%, and 20% of respondents reported a perceived increased use of these products, and 30% reported an increased frequency of reopening for bleeding. Apart from knowledge regarding local aprotinin stock, there was no significant difference in opinions between surgeons and anesthesiologists.


CONCLUSIONS
While the majority of respondents felt that the suspension of the license for aprotinin had no effect, almost a third felt it had impacted negatively on the care of patients undergoing cardiac surgery.
McMullan
Victoria
V
Department of Anaesthesia, Critical Care and Pain Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. vmcmullan@doctors.org.uk
Alston
R Peter
RP
D000776:Anesthesiology; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D007611:Aprotinin / Q000009:adverse effects*; D001291:Attitude of Health Personnel; D019538:Health Care Surveys; D006487:Hemostasis; D006490:Hemostatics / Q000009:adverse effects*; D006801:Humans; D008004:Licensure; D010820:Physicians; D011182:Postoperative Care / Q000706:statistics & numerical data*; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D057051:Product Recalls and Withdrawals; D011795:Surveys and Questionnaires; D013903:Thoracic Surgery; D014148:Tranexamic Acid / Q000627:therapeutic use; D006113:United Kingdom
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D014148:Tranexamic Acid; D007611:Aprotinin